
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5155302/publications.pdf Version: 2024-02-01



STEN MYDEHAUC

#	Article	IF	CITATIONS
1	Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leukemia and Lymphoma, 2008, 49, 1486-1493.	0.6	144
2	Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review. Journal of Neurosurgery: Spine, 2017, 27, 428-435.	0.9	113
3	Vertebral Compression Fracture After Spine Stereotactic Body Radiation Therapy: A Review of the Pathophysiology and Risk Factors. Neurosurgery, 2018, 83, 314-322.	0.6	104
4	Imaging-Based Outcomes for 24ÂGy in 2 Daily Fractions for Patients with de Novo Spinal Metastases Treated With Spine Stereotactic Body Radiation Therapy (SBRT). International Journal of Radiation Oncology Biology Physics, 2018, 102, 499-507.	0.4	83
5	MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. Science Translational Medicine, 2021, 13, eabj4011.	5.8	82
6	Spine Stereotactic Body Radiotherapy: Indications, Outcomes, and Points of Caution. Global Spine Journal, 2017, 7, 179-197.	1.2	79
7	Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview. Frontiers in Oncology, 2019, 9, 337.	1.3	74
8	A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood, 2010, 116, 2237-2240.	0.6	63
9	Differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiotherapy: utility of intravoxel incoherent motion perfusion MRI and correlation with histopathology. Journal of Neuro-Oncology, 2017, 134, 433-441.	1.4	59
10	Evaluation of Glioblastoma Response to Therapy With Chemical Exchange Saturation Transfer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 713-723.	0.4	58
11	Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. Journal of Thoracic Oncology,	0.5	58
12	Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Practical Radiation Oncology, 2020, 10, e495-e507.	1.1	50
13	Quantitative MRI Biomarkers of Stereotactic Radiotherapy Outcome in Brain Metastasis. Scientific Reports, 2019, 9, 19830.	1.6	46
14	Quantitative ⁶⁸ Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ¹⁷⁷ Lu-DOTATATE. Journal of Nuclear Medicine, 2021, 62, 1406-1414.	2.8	40
15	Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases. Neuro-Oncology, 2020, 22, 84-93.	0.6	39
16	Adverse Radiation Effect After Hypofractionated Stereotactic Radiosurgery in 5 Daily Fractions for Surgical Cavities and Intact Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2020, 106, 772-779.	0.4	36
17	Quantitating Interfraction Target Dynamics During Concurrent Chemoradiation for Glioblastoma: A Prospective Serial Imaging Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 736-746.	0.4	36
18	Volume of Lytic Vertebral Body Metastatic Disease Quantified Using Computed Tomography–Based Image Segmentation Predicts Fracture Risk After Spine Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 75-81.	0.4	35

#	Article	IF	CITATIONS
19	Image-Guided, Linac-Based, Surgical Cavity-Hypofractionated Stereotactic Radiotherapy in 5 Daily Fractions for Brain Metastases. Neurosurgery, 2019, 85, E860-E869.	0.6	34
20	A Treatment Planning and Acute Toxicity Comparison of Two Pelvic Nodal Volume Delineation Techniques and Delivery Comparison of Intensity-Modulated Radiotherapy Versus Volumetric Modulated Arc Therapy for Hypofractionated High-Risk Prostate Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, e657-e662.	0.4	32
21	Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy. Scientific Reports, 2018, 8, 2475.	1.6	31
22	Spinal metastasis: diagnosis, management and follow-up. British Journal of Radiology, 2019, 92, 20190211.	1.0	29
23	MRI radiomics to differentiate between low grade glioma and glioblastoma peritumoral region. Journal of Neuro-Oncology, 2021, 155, 181-191.	1.4	29
24	Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Expert Review of Anticancer Therapy, 2016, 16, 523-530.	1.1	28
25	Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter. Radiotherapy and Oncology, 2020, 142, 236-245.	0.3	27
26	Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Frontiers in Oncology, 2021, 11, 628155.	1.3	27
27	Postoperative Stereotactic Body Radiotherapy for Spinal Metastases and the Impact of Epidural Disease Grade. Neurosurgery, 2019, 85, E1111-E1118.	0.6	26
28	Glioma consensus contouring recommendations from a MR-Linac International Consortium Research Group and evaluation of a CT-MRI and MRI-only workflow. Journal of Neuro-Oncology, 2020, 149, 305-314.	1.4	25
29	Local control and patterns of failure for "Radioresistant―spinal metastases following stereotactic body radiotherapy compared to a "Radiosensitive―reference. Journal of Neuro-Oncology, 2021, 152, 173-182.	1.4	24
30	Single-Fraction Stereotactic Radiosurgery Versus Hippocampal-Avoidance Whole Brain Radiation Therapy for Patients With 10 to 30 Brain Metastases: A Dosimetric Analysis. International Journal of Radiation Oncology Biology Physics, 2019, 105, 394-399.	0.4	23
31	Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation. Journal of Neuro-Oncology, 2021, 151, 267-278.	1.4	23
32	Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. Cmaj, 2019, 191, E574-E580.	0.9	21
33	Stereotactic Body Radiotherapy for Spinal Metastases at the Extreme Ends of the Spine: Imaging-Based Outcomes for Cervical and Sacral Metastases. Neurosurgery, 2019, 85, 605-612.	0.6	20
34	Accuracy and precision of apparent diffusion coefficient measurements on a 1.5ÂT MR-Linac in central nervous system tumour patients. Radiotherapy and Oncology, 2021, 164, 155-162.	0.3	19
35	Glioblastoma (GBM) effects on quantitative MRI of contralateral normal appearing white matter. Journal of Neuro-Oncology, 2018, 139, 97-106.	1.4	18
36	Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. Radiotherapy and Oncology, 2021, 156, 258-265.	0.3	18

#	Article	IF	CITATIONS
37	Quantitative mapping of individual voxels in the peritumoral region of IDH-wildtype glioblastoma to distinguish between tumor infiltration and edema. Journal of Neuro-Oncology, 2021, 153, 251-261.	1.4	18
38	Spinal metastases: multimodality imaging in diagnosis and stereotactic body radiation therapy planning. Future Oncology, 2017, 13, 77-91.	1.1	17
39	The era of stereotactic body radiotherapy for spinal metastases and the multidisciplinary management of complex cases. Neuro-Oncology Practice, 2016, 3, 48-58.	1.0	16
40	Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes. Oncologist, 2019, 24, 1384-1394.	1.9	16
41	Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters. Radiotherapy and Oncology, 2021, 161, 159-165.	0.3	14
42	Hypofractionated Stereotactic Radiation Therapy for Intact Brain Metastases in 5 Daily Fractions: Effect of Dose on Treatment Response. International Journal of Radiation Oncology Biology Physics, 2022, 112, 342-350.	0.4	14
43	Chemical exchange saturation transfer MRI in central nervous system tumours on a 1.5ÂT MR-Linac. Radiotherapy and Oncology, 2021, 162, 140-149.	0.3	14
44	Prognostic Factors Associated With Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events. Neurosurgery, 2021, 88, 971-979.	0.6	13
45	Material deprivation and access to cancer care in a universal health care system. Cancer, 2020, 126, 4545-4552.	2.0	12
46	Postoperative stereotactic body radiotherapy for spinal metastases. Chinese Clinical Oncology, 2017, 6, S18-S18.	0.4	12
47	Inter-fraction dynamics during post-operative 5 fraction cavity hypofractionated stereotactic radiotherapy with a MR LINAC: a prospective serial imaging study. Journal of Neuro-Oncology, 2022, 156, 569-577.	1.4	12
48	A rapid inversion technique for the measurement of longitudinal relaxation times of brain metabolites: application to lactate in highâ€grade gliomas at 3 T. NMR in Biomedicine, 2016, 29, 1381-1390.	1.6	10
49	Positional Accuracy of Treating Multiple Versus Single Vertebral Metastases With Stereotactic Body Radiotherapy. Technology in Cancer Research and Treatment, 2017, 16, 231-237.	0.8	10
50	Mature Imaging-Based Outcomes Supporting Local Control for Complex Reirradiation Salvage Spine Stereotactic Body Radiotherapy. Neurosurgery, 2020, 87, 816-822.	0.6	10
51	Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms: A Preliminary Study. Neuroendocrinology, 2022, 112, 153-160.	1.2	10
52	A randomized phase II/III study comparing stereotactic body radiotherapy (SBRT) versus conventional palliative radiotherapy (CRT) for patients with spinal metastases (NCT02512965) Journal of Clinical Oncology, 2017, 35, TPS10129-TPS10129.	0.8	10
53	Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis. Technology in Cancer Research and Treatment, 2022, 21, 153303382211096.	0.8	9
54	BRAF V600E mutant oligodendrogliomaâ€like tumors with chromosomal instability in adolescents and young adults. Brain Pathology, 2020, 30, 515-523.	2.1	8

#	Article	IF	CITATIONS
55	Stereotactic radiosurgery for resected brain metastasis: Cavity dynamics and factors affecting its evolution. Journal of Radiosurgery and SBRT, 2018, 5, 191-200.	0.2	8
56	Improved dosimetric accuracy with semiâ€automatic contour propagation of organsâ€atâ€risk in glioblastoma patients undergoing chemoradiation. Journal of Applied Clinical Medical Physics, 2019, 20, 45-53.	0.8	7
57	The Initial Step Towards Establishing a Quantitative, Magnetic Resonance Imaging-Based Framework for Response Assessment of Spinal Metastases After Stereotactic Body Radiation Therapy. Neurosurgery, 2021, 89, 884-891.	0.6	6
58	Spine Stereotactic Body Radiotherapy for Prostate Cancer Metastases and the Impact of Hormone Sensitivity Status on Local Control. Neurosurgery, 2022, 90, 743-749.	0.6	6
59	Why hypofractionate stereotactic radiosurgery for brain metastases?. CNS Oncology, 2016, 5, 111-113.	1.2	5
60	Clinical Image Coregistration Variability on a Dedicated Radiosurgery Unit. Neurosurgery, 2019, 85, E101-E108.	0.6	5
61	Quantification of pulsed saturation transfer at 1.5T and 3T. Magnetic Resonance in Medicine, 2019, 82, 1684-1699.	1.9	5
62	Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors: A Population-Based Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 935-944.	2.3	5
63	Predicting survival in patients with glioblastoma using MRI radiomic features extracted from radiation planning volumes. Journal of Neuro-Oncology, 2022, 156, 579-588.	1.4	5
64	A pilot study of everolimus and radiation for neuroendocrine liver metastases. Endocrine-Related Cancer, 2021, 28, 541-548.	1.6	4
65	Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors. JAMA Oncology, 2021, 7, 1718.	3.4	4
66	Rapidly progressive bone destruction of the finger as first presentation of systemic metastases from lung cancer. BMJ Case Reports, 2010, 2010, bcr0520091912-bcr0520091912.	0.2	4
67	Economic Analysis of Adjuvant Chemoradiotherapy Compared with Chemotherapy in Resected Pancreas Cancer. Annals of Surgical Oncology, 2019, 26, 4193-4203.	0.7	3
68	ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma. Data in Brief, 2021, 35, 106950.	0.5	3
69	Investigation of irradiated volume in linac-based brain hypo-fractionated stereotactic radiotherapy. Radiation Oncology, 2017, 12, 117.	1.2	2
70	The benefits of upfront primary tumor resection for metastatic small bowel neuroendocrine tumors: A population-based analysis Journal of Clinical Oncology, 2020, 38, 620-620.	0.8	2
71	Symptom burden at the end of life for neuroendocrine tumors: A population-based analysis of patient-reported outcomes Journal of Clinical Oncology, 2019, 37, 297-297.	0.8	2
72	Survival and cost associated with chemotherapy and chemoradiotherapy among resected pancreas cancer patients Journal of Clinical Oncology, 2019, 37, 351-351.	0.8	1

#	Article	IF	CITATIONS
73	Proof of concept for stereotactic body radiation therapy in the treatment of functional neuroendocrine neoplasms. Journal of Radiosurgery and SBRT, 2020, 6, 321-324.	0.2	1
74	LGG-01. BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENT AND YOUNG ADULT. Neuro-Oncology, 2019, 21, ii98-ii98.	0.6	0
75	Hospitalizations in elderly glioblastoma patients Journal of Clinical Oncology, 2017, 35, e21529-e21529.	0.8	Ο
76	Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors: A population-based analysis Journal of Clinical Oncology, 2020, 38, 4605-4605.	0.8	0